- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Immunoprecise Antibodies Ltd (IPA)
Immunoprecise Antibodies Ltd stock price live, this page displays NASDAQ IPA stock exchange data. View the IPA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Immunoprecise Antibodies Ltd real time stock price chart below.
What Is the Immunoprecise Antibodies Ltd Stock Price Today?
The Immunoprecise Antibodies Ltd stock price today is 2.760.
What Is the Stock Symbol for Immunoprecise Antibodies Ltd?
The stock symbol for Immunoprecise Antibodies Ltd is ""IPA.""
What Stock Exchange Does Immunoprecise Antibodies Ltd Trade On?
Immunoprecise Antibodies Ltd is listed and trades on the NASDAQ stock exchange.
Is Immunoprecise Antibodies Ltd a Good Stock to Buy?
Determining whether Immunoprecise Antibodies Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IPA quote. (ISIN: CA45257F2008)
What Is the Immunoprecise Antibodies Ltd Stock Price Today?
The Immunoprecise Antibodies Ltd stock price today is 2.760.
What Is the Stock Symbol for Immunoprecise Antibodies Ltd?
The stock symbol for Immunoprecise Antibodies Ltd is ""IPA.""
What Stock Exchange Does Immunoprecise Antibodies Ltd Trade On?
Immunoprecise Antibodies Ltd is listed and trades on the NASDAQ stock exchange.
Is Immunoprecise Antibodies Ltd a Good Stock to Buy?
Determining whether Immunoprecise Antibodies Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IPA quote. (ISIN: CA45257F2008)
NASDAQ
Currency in USD
Fair Value
An estimate of a Immunoprecise's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.710
3.246
52 wk Range
0.270
3.246
IPA Scorecard
Full Analysis
Analysts do not anticipate the company will be profitable this year
Trading near 52-week High
1/2
Fair Value
An estimate of a Immunoprecise's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.7103.246
52 wk Range
0.2703.246
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
IPA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Immunoprecise's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
4.000
Upside
+44.93%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High return over the last year
- Form 6K Immunoprecise Antibodies Ltd For: 24 July
- Investing.com
- Form 6K Immunoprecise Antibodies Ltd For: 21 July
- Investing.com
- Form 6K Immunoprecise Antibodies Ltd For: 29 July
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral
Immunoprecise Antibodies Ltd Company Profile
ImmunoPrecise Antibodies Ltd. operates as an AI-driven biotherapeutic research, technology, and scientifically robust life science company. It discovers and develops customized and novel antibodies by generating proprietary and patented processes, procedures, and innovative approaches to antibody discovery, development, and production. The company was incorporated in 1983 and is headquartered in Austin, Texas.
Immunoprecise Antibodies Ltd Earnings Call Summary for Q4/2025
- ImmunoPrecise reported record Q4 revenue of $7M, with gross margin improving to 64% from 48% YoY, despite a 14.74% stock price drop post-earnings
- BioStrand segment grew 180% YoY, driven by increased interest in AI-driven preclinical drug development; company expects continued growth in this area
- Company completing divestiture of Dutch subsidiary and rebranding to emphasize AI platform capabilities; anticipates revenue from oncology partnership in Q2
- CEO Jennifer Bass highlighted positioning for 'earlier insights, stronger candidate selection, and faster decision making at scale' in drug development
- Despite positive financials, stock fell sharply, potentially reflecting broader market concerns or undisclosed company-specific factors
Last Updated: 29/07/2025, 17:08
Read Full TranscriptCompare IPA to Peers and Sector
Metrics to compare | IPA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIPAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.8x | −1.7x | −0.6x | |
PEG Ratio | −0.53 | −0.01 | 0.00 | |
Price/Book | 7.5x | 1.3x | 2.6x | |
Price / LTM Sales | 7.2x | 2.7x | 3.3x | |
Upside (Analyst Target) | 44.9% | 28.5% | 39.0% | |
Fair Value Upside | Unlock | 18.9% | 4.9% | Unlock |
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 4.000
(+44.93% Upside)
Earnings
Latest Release
Jul 29, 2025
EPS / Forecast
-0.05 / -0.07
Revenue / Forecast
6.98M / --
People Also Watch
FAQ
What Stock Exchange Does Immunoprecise Trade On?
Immunoprecise is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Immunoprecise?
The stock symbol for Immunoprecise is "IPA."
What Is the Immunoprecise Market Cap?
As of today, Immunoprecise market cap is 128.08M.
What Is Immunoprecise's Earnings Per Share (TTM)?
The Immunoprecise EPS (TTM) is -0.91.
From a Technical Analysis Perspective, Is IPA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Immunoprecise Stock Split?
Immunoprecise has split 1 times.
How Many Employees Does Immunoprecise Have?
Immunoprecise has 92 employees.
What is the current trading status of Immunoprecise (IPA)?
As of 26 Aug 2025, Immunoprecise (IPA) is trading at a price of 2.76, with a previous close of 2.76. The stock has fluctuated within a day range of 2.71 to 3.25, while its 52-week range spans from 0.27 to 3.25.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.